TIGAR/C12orf5 Antibody [FITC]

This conjugate is made on demand. Actual recovery may vary from the stated volume of this product. The volume will be greater than or equal to the unit size stated on the datasheet.

TIGAR (TP53-induced glycolysis and apoptosis regulator), a member of phosphoglycerate mutase family, is a target gene of p53 and it regulates glucose metabolism in cancer cells by acting as a fructose-bisphosphatase hydrolyzing fructose-2,6-bisphosphate (Fru-2,6-P2 ) and Fru-1,6-P2 leading to decreased Fru-2,6-P2 levels with subsequent reduction in PFK1 (phosphofructosekinase-1) activity as well as negative regulation of glycolysis. TIGAR also reduces cellular ROS through its translocation to the mitochondria where it interacts with HK2 leading to enhanced HK2 activity, regulation of mitochondrial membrane potential, and decreased mitochondrial ROS which ultimately protects the cells from DNA damage-induced apoptosis. Moreover, TIGAR mediated negative regulation of glycolysis leads to redirection of glycolytic metabolic intermediates towards pentose phosphate pathway's oxidative branch that follows increased cellular NADPH production, ROS scavenging by GSH and thus a lower sensitivity of cells to oxidative stress-associated apoptosis, including that induced by p53. Because of TIGAR's anti-apoptotic/protective role, it has been proposed to implicate in cell-cycle arrest and DNA repair effector response in cells that suffer from repairable dose of genotoxic/cellular insult.

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Array NBP1-49534F

• TIGAR/C12orf5 Antibodies
• TIGAR/C12orf5 Lysate
• TIGAR/C12orf5 Proteins
• TIGAR/C12orf5 Proteins and Enzyme